Barrett's esophagus, apoptosis and cell cycle regulation: Correlation of p53 with Bax, Bcl-2 and p21 protein expression

Anticancer Research

Volumn 20, Issue 4, 2000, Pages 2427-2432

  Woodward, Timothy A ^a   Klingler, Paul D ^a   Genko, Petrina V ^a   Wolfe, James T ^a  

^a MAYO CLINIC   (United States)

Author keywords

Apoptosis cell cycle p53; Barrett's esophagus; Bax; Bcl 2; P21

Indexed keywords

PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53;

APOPTOSIS; ARTICLE; BARRETT ESOPHAGUS; CELL CYCLE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; APOPTOSIS; BARRETT ESOPHAGUS; BCL-2-ASSOCIATED X PROTEIN; CELL CYCLE; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; IMMUNOHISTOCHEMISTRY; MICE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RABBITS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033865127     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Haggitt RC: Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol 25: 982-993, 1994.
2. Lee JM, Bernstein A: Apoptosis, cancer and the p53 tumour suppressor gene. Cancer Metastasis Rev 14: 149-161, 1995.
3. Vogelstein B, Kinzler KW: p53 function and dysfunction. Cell 70: 523-526, 1992.
4. Harper JW, Adami GR, Wei N et al: The p21 Cdk-interacting protein Cipl is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816, 1993.
5. Xiong Y, Hannon GJ, Zhang H et al: p21 is a universal inhibito, r of cyclin kinases. Nature 366: 701-704, 1993.
6. Waga S, Hannon GJ, Beach D et al: The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369: 574-578, 1994.
7. el-Deiry WS, Tokino T, Velculescu VE et al: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993.
8. Yin C, Knudson CM, Korsmeyer SJ et al: Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 385: 637-640, 1997.
9. Younes M, Ertan A, Lechago LV et al: p53 Protein accumulation is a specific marker of malignant potential in Barrett's metaplasia. Dig Dis Sci 42: 697-701, 1997.
10. Wang DY, Xiang YY, Tanaka M et al: High prevalence of p53 protein overexpression in patients with esophageal cancer in Linxian, China and its relationship to progression and prognosis. Cancer 74: 3089-3096, 1994.
11. Parenti AR, Rugge M, Frizzera E et al: p53 overexpression in the multistep process of esophageal carcinogenesis. Am J Surg Pathol 19: 1418-22, 1995.
12. Belluco C, Guillem JG, Kemeny N et al: p53 nuclear protein overexpression in colorectal cancer: a dominant predictor of survival in patients with advanced hepatic metastases. J Clin Oncol 14: 2696-2701, 1996.
13. Moreira LF, Naomoto Y, Hamada M et al: Assessment of apoptosis in oesophageal carcinoma preoperatively treated by chemotherapy and radiotherapy. Anticancer Res 15: 639-644, 1995.
14. Ohbu M, Saegusa M, Okayasu I: Apoptosis and cellular proliferation in oesophageal squamous cell carcinomas: differences between keratinizing and nonkeratinizing types. Virchows Arch 427: 271-276, 1995.
15. Katada N, Hinder RA, Smyrk TC et al: Apoptosis is inhibited early in the dysplasia-carcinoma sequence of Barrett esophagus. Arch Surg 132: 728-733, 1997.
16. Moskaluk CA, Heitmiller R, Zahurak M et al: p53 and p21 (WAF1/CIP1/SDI1) gene products in Barrett esophagus and adenocarcinoma of the esophagus and esophagogastric junction. Hum Pathol 27: 1211-1220, 1996.
17. Baas IO, Mulder JW, Offerhaus GJ et al: An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 172: 5-12, 1994.
18. Krajewski S, Krajewska M, Ehrmann J et al: Immunohistochemical analysis of Bcl-2, Bcl-X, Mcl-1, and Bax in tumors of central and peripheral nervous system origin. Am J Pathol 150: 805-814, 1997.